Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Cost of RevenueEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsReceivables - Net
Ratios

Outlook Therapeutics (OTLK) Accumulated Depreciation & Amortization (2016 - 2020)

Outlook Therapeutics (OTLK) has disclosed Accumulated Depreciation & Amortization for 6 consecutive years, with $178510.0 as the latest value for Q2 2020.

  • On a quarterly basis, Accumulated Depreciation & Amortization fell 92.78% to $178510.0 in Q2 2020 year-over-year; TTM through Jun 2020 was $178510.0, a 92.78% decrease, with the full-year FY2019 number at $3.4 million, up 10.07% from a year prior.
  • Accumulated Depreciation & Amortization was $178510.0 for Q2 2020 at Outlook Therapeutics, up from $63775.0 in the prior quarter.
  • In the past five years, Accumulated Depreciation & Amortization ranged from a high of $3.4 million in Q3 2019 to a low of $63775.0 in Q1 2020.
  • A 5-year average of $1.2 million and a median of $693206.5 in 2017 define the central range for Accumulated Depreciation & Amortization.
  • Peak YoY movement for Accumulated Depreciation & Amortization: soared 200.83% in 2019, then tumbled 96.11% in 2020.
  • Outlook Therapeutics' Accumulated Depreciation & Amortization stood at $669780.0 in 2016, then grew by 1.02% to $676624.0 in 2017, then rose by 21.64% to $823077.0 in 2018, then plummeted by 92.25% to $63776.0 in 2019, then surged by 179.9% to $178510.0 in 2020.
  • Per Business Quant, the three most recent readings for OTLK's Accumulated Depreciation & Amortization are $178510.0 (Q2 2020), $63775.0 (Q1 2020), and $63776.0 (Q4 2019).